Phase II Study of Gefitinib in Triple-negative, EGFR Positive Metastatic Breast Cancer
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Gefitinib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 21 Dec 2012 New trial record